Qsemble Capital Management LP Buys Shares of 63,284 Edwards Lifesciences Co. (NYSE:EW)

Qsemble Capital Management LP acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 63,284 shares of the medical research company’s stock, valued at approximately $4,176,000.

A number of other hedge funds also recently made changes to their positions in EW. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $29,000. Webster Bank N. A. acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $39,000. Versant Capital Management Inc boosted its holdings in shares of Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after buying an additional 326 shares in the last quarter. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Finally, Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW stock traded down $0.14 during mid-day trading on Monday, hitting $70.34. The company had a trading volume of 440,055 shares, compared to its average volume of 4,622,331. The company has a market capitalization of $41.49 billion, a P/E ratio of 10.17, a P/E/G ratio of 3.96 and a beta of 1.12. The stock’s 50 day moving average price is $67.70 and its 200-day moving average price is $75.59. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the company posted $0.59 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,000 shares of company stock worth $2,657,000. 1.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Citigroup decreased their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Canaccord Genuity Group lowered their target price on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, October 25th. Finally, Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.